XML 158 R64.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended 53 Months Ended
May 21, 2020
Feb. 14, 2020
Apr. 30, 2018
Jun. 30, 2016
Jan. 31, 2016
Jan. 31, 2015
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
May 31, 2019
Jan. 01, 2019
Jun. 30, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Deferred revenue               $ 3,842,307 $ (44,119) $ (65,260)      
Remaining performance obligations             $ 87,225 87,225          
Increase to the transaction price               (7,100)          
Aggregate net proceeds from the offering $ 1,300,000 $ 549,500                      
Deferred revenue             4,044,612 4,044,612 202,305        
Additions               4,009,960          
Collaboration revenue                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Deferred revenue             240,182 240,182 199,528        
Additions               121,882          
Merck agreement 2015                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Deferred revenue                     $ 50,000    
Proceeds from equity investment           $ 50,000              
Initial research period                     4 years    
Remaining performance obligations             52,647 52,647 59,735     $ 65,000  
Performance period                     3 years    
Increase to the transaction price               12,353 5,265        
Additions         $ 10,000                
Merck agreement 2015 | Collaboration revenue                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue from contract with customer, excluding assessed tax               62 492 24,582      
Separate agreements with Merck | Collaboration revenue                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue from contract with customer, excluding assessed tax               (7,026) (4,773) 24,582      
PCV Agreement                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Estimated arrangement consideration                         $ 250,000
Additions       $ 200,000                  
PCV Agreement | Series H Redeemable Convertible Preferred Stock                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Aggregate net proceeds from the offering     $ 125,000                    
Premium recorded to deferred revenue     13,000                    
PCV Agreement | PCV products                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Estimated arrangement consideration     $ 243,000       243,000 243,000 243,000        
PCVSAV Agreement                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Remaining performance obligations             213,360 213,360 213,050        
Deferred revenue             51,007 51,007 83,799        
PCVSAV Agreement | Collaboration revenue                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue from contract with customer, excluding assessed tax               33,103 41,382 $ 41,498      
Increase to the transaction price             3,500 3,500          
Upfront payment | Merck agreement 2015                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Remaining performance obligations             60,000 60,000 60,000     60,000  
Upfront payment | PCVSAV Agreement                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Remaining performance obligations             200,000 200,000 200,000        
Milestone payment | Merck agreement 2015                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue from contract with customer, excluding assessed tax                     $ 5,000    
Remaining performance obligations                       $ 5,000  
Premium associated with the contemporaneous sale of Series H redeemable convertible preferred stock | PCVSAV Agreement                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Remaining performance obligations             13,050 13,050 13,050        
Upfront Payment, Research And Development | Merck agreement 2015                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Remaining performance obligations             5,000 5,000 $ 5,000        
PCV Performance Obligation | PCVSAV Agreement                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Remaining performance obligations             206,356 206,356          
KRAS Performance Obligation | PCVSAV Agreement                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Remaining performance obligations             $ 7,004 $ 7,004